Amgen's Phase 2 MariTide Data to be Unveiled at ADA's 85th Scientific Sessions
Amgen, a leading biotechnology company, has exciting news as it prepares to present the results from the first phase of its ongoing 2nd phase study on MariTide (formerly known as AMG 133). Scheduled to occur at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20 to June 23, 2025, in Chicago, this presentation is highly anticipated in the medical community. MariTide is an innovative peptide-antibody conjugate aimed at addressing obesity and Type 2 diabetes, two interconnected public health challenges.
The study examines MariTide's efficacy and safety over a 52-week period among participants with obesity, both with and without Type 2 diabetes. This is particularly significant as the project reflects a commitment to tackling obesity rates that have more than doubled globally since 1990. The efficacy data are promising, showcasing robust weight loss without the typical plateau often observed in many anti-obesity treatments, a crucial aspect noted by Dr. Jay Bradner, Amgen's Executive Vice President of Research and Development.
Key results from the study were initially released in November 2024, revealing how participants achieved significant weight loss, prompting excitement for the upcoming symposium. The presentations on June 23, from 1:30 PM to 3:00 PM CDT, will delve into the details, including real-world applications and a comparative analysis against prior pharmacokinetics studies. This reveals Amgen's strategic approach in refining the design and intention of their Phase 3 MARITIME trials.
Beyond solely focusing on MariTide, Amgen will also provide updates on the Repatha® therapy, a medication targeting cardiovascular health by lowering LDL cholesterol levels. Presenting data from the Phase 3 FOURIER trial, the company continues to unveil the interconnectedness of obesity and cardiovascular diseases at this well-respected conference.
Obesity is not merely a cosmetic issue; it's a chronic disease leading to multiple serious health conditions. The American Medical Association and the European Health Commission have both recognized obesity as such, underscoring the importance of comprehensive treatment approaches, especially medication interventions, which are currently underutilized.
MariTide represents a dual approach as a glucagon-like peptide 1 receptor agonist and glucose-dependent insulinotropic polypeptide receptor antagonist, potentially offering benefits that go beyond existing treatments. Unlike traditional medications that may encourage weight regain post-treatment, the longer half-life and dual-action mechanism of MariTide provide a promising avenue for effective long-term weight management.
Addressing obesity requires a multifaceted approach, and Amgen has acknowledged this by developing a broad pipeline for obesity treatment that spans both oral and injectable forms. Their commitment extends beyond addressing weight issues alone; they aim to tackle related conditions and improve overall patients' quality of life.
At the ADA sessions, Amgen will also participate in the Interactive Obesity Experience, allowing attendees to contribute to a collective word cloud project related to the discourse on obesity and partake in insightful discussions within their designated booth. While the live sessions of the ADA Scientific Sessions won’t be streamed, key presentations will be available on-demand following the conference.
The upcoming symposium highlights the importance of Amgen's ongoing commitment to advancing our understanding and treatment of chronic conditions that significantly affect millions of lives. With the world observing a dire need for effective interventions amidst rising obesity and Type 2 diabetes rates, the findings and discussions presented at this year's ADA events will undoubtedly hold great significance for future healthcare strategies. As innovations like MariTide strive to become standouts in the fight against obesity, the collaborative efforts between biotechnology firms and the healthcare community continue to play a pivotal role in stemming the tide of chronic diseases worldwide.
The study examines MariTide's efficacy and safety over a 52-week period among participants with obesity, both with and without Type 2 diabetes. This is particularly significant as the project reflects a commitment to tackling obesity rates that have more than doubled globally since 1990. The efficacy data are promising, showcasing robust weight loss without the typical plateau often observed in many anti-obesity treatments, a crucial aspect noted by Dr. Jay Bradner, Amgen's Executive Vice President of Research and Development.
Key results from the study were initially released in November 2024, revealing how participants achieved significant weight loss, prompting excitement for the upcoming symposium. The presentations on June 23, from 1:30 PM to 3:00 PM CDT, will delve into the details, including real-world applications and a comparative analysis against prior pharmacokinetics studies. This reveals Amgen's strategic approach in refining the design and intention of their Phase 3 MARITIME trials.
Beyond solely focusing on MariTide, Amgen will also provide updates on the Repatha® therapy, a medication targeting cardiovascular health by lowering LDL cholesterol levels. Presenting data from the Phase 3 FOURIER trial, the company continues to unveil the interconnectedness of obesity and cardiovascular diseases at this well-respected conference.
Obesity is not merely a cosmetic issue; it's a chronic disease leading to multiple serious health conditions. The American Medical Association and the European Health Commission have both recognized obesity as such, underscoring the importance of comprehensive treatment approaches, especially medication interventions, which are currently underutilized.
MariTide represents a dual approach as a glucagon-like peptide 1 receptor agonist and glucose-dependent insulinotropic polypeptide receptor antagonist, potentially offering benefits that go beyond existing treatments. Unlike traditional medications that may encourage weight regain post-treatment, the longer half-life and dual-action mechanism of MariTide provide a promising avenue for effective long-term weight management.
Addressing obesity requires a multifaceted approach, and Amgen has acknowledged this by developing a broad pipeline for obesity treatment that spans both oral and injectable forms. Their commitment extends beyond addressing weight issues alone; they aim to tackle related conditions and improve overall patients' quality of life.
At the ADA sessions, Amgen will also participate in the Interactive Obesity Experience, allowing attendees to contribute to a collective word cloud project related to the discourse on obesity and partake in insightful discussions within their designated booth. While the live sessions of the ADA Scientific Sessions won’t be streamed, key presentations will be available on-demand following the conference.
The upcoming symposium highlights the importance of Amgen's ongoing commitment to advancing our understanding and treatment of chronic conditions that significantly affect millions of lives. With the world observing a dire need for effective interventions amidst rising obesity and Type 2 diabetes rates, the findings and discussions presented at this year's ADA events will undoubtedly hold great significance for future healthcare strategies. As innovations like MariTide strive to become standouts in the fight against obesity, the collaborative efforts between biotechnology firms and the healthcare community continue to play a pivotal role in stemming the tide of chronic diseases worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.